Midland, in Partnership with Rio Tinto Exploration Canada, Intersects New Lithium and Cesium Bearing Pegmatites During the 2025 Drilling Program on the Galinee Project

(TSX-V:MD),(TSX-V:MD), MONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with Rio Tinto Exploration Canada Inc. (“RTEC“), is pleased to announce the results of the 2025 drilling campaign for lithium on the Galinee project. The Galinee project is located approximately 5 kilometres east of the Adina lithium deposit held […]

GURU Organic Energy to Report Fourth Quarter and Fiscal Year 2025 Results

(TSX:GURU), MONTRÉAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company“), Canada's leading organic energy drink brand1, will report its financial results for the fourth quarter and fiscal year ended October 31, 2025 on Thursday, January 22, 2026, before markets open. Management will hold a conference call to

Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference

(NASDAQ:ZVRA), CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

(NYSE:ENOV), Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) — Enovis(TM) Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link

Beneficient Enters into $3 Million GP Primary Capital Transaction

(NASDAQ:BENF), DALLAS, Jan. 08, 2026 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced it has closed on the financing of an approximately $3 million primary capital commitment for Cork &

Public Affairs, Reputation and Issues Management Expert Joshua Baca Joins FTI Consulting

(NYSE:FCN), WASHINGTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Joshua Baca as a Senior Managing Director. Mr. Baca, who is based in Washington, D.C., joins FTI Consulting's Strategic Communications segment with more than 20 years of experience at the intersection of government, business and reputation. In

AGF Investments Launches ETF Series for Legacy Funds: AGF American Growth Fund and AGF Global Select Fund

(TSX:AGF-B),(TSX:AGF.B),(TSX:AGFB),(TSX:AMGR),(TSX:AGSL), TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) announced today the launch of ETF series units for AGF American Growth Fund and AGF Global Select Fund, providing investors with access to legacy funds with long-standing, proven track records in an ETF series. “This launch expands our ETF lineup and responds

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 GlobeNewswire January 08, 2026 Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases GlobeNewswire January 08, 2026 Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist, designed for durable weight management

ZenaTech Completes 20th Acquisition in Year One of Drone as a Service, Strengthening California Wildfire Management and Public Works Opportunities

ZenaTech Completes 20th Acquisition in Year One of Drone as a Service, Strengthening California Wildfire Management and Public Works Opportunities GlobeNewswire January 08, 2026 VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a

Scroll to Top